Actively Recruiting
Study of the Gut Microbiomes Role in Immune Checkpoint Inhibitor Therapy for Lung, Skin, Kidney, and Breast Cancers
Led by VastBiome · Updated on 2022-04-27
800
Participants Needed
1
Research Sites
261 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating how the gut microbiome affects the response to immune checkpoint inhibitor ICI therapy in patients with several types of solid tumors, including non-small-cell lung carcinoma, malignant melanoma, renal cell carcinoma, and triple-negative breast cancer. This observational study aims to understand the connections between gut microbiota, the immune system, and treatment outcomes by collecting and analyzing samples from patients undergoing similar immunotherapy but experiencing different results. The study is sponsored by VastBiome and focuses on large-scale, prospective data collection with standardized methods. Participants in this study will be treated with immune checkpoint inhibitors such as anti-PD-1, anti-PD-L1, or anti-CTLA-4 agents, either alone or combined with other treatments like chemotherapy, targeted therapy, surgery, or radiation, following FDA-approved uses. Stool samples will be collected before starting checkpoint therapy and again after approximately 6 to 8 weeks, at the end of Cycle 2 of treatment, to assess changes in microbiome composition. Blood samples and other biomarkers will also be analyzed during this period to explore their relationships with microbiome changes and treatment effects. Throughout the study, 800 patients will provide stool specimens and complete questionnaires in English or Spanish. Researchers will monitor microbiome composition changes from baseline through Cycle 2 of therapy, correlating these with blood biomarkers and clinical outcomes. Patients will be screened for COVID-19 symptoms and must be able to provide informed consent. The study excludes individuals with mental incapacity, pregnancy, active brain metastases, or those participating in other immuno-oncology trials. Participation involves sample collection and questionnaire completion, with the total observation period centered around the initial 6 to 8 weeks of immunotherapy.
CONDITIONS
Brief Title
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
Research Team
H
Hanane Arib, MS
P
Peter McCaffrey, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here